Stocks
18 articles on Stocks, researched and written by the Shotlee Editorial Team from primary sources.
China Adds Second GLP-1 Diabetes Drug to Essential Medicine List
China includes injectable semaglutide on its National Essential Drug List, improving access for diabetes patients while excluding obesity indications from the policy.
7 min read
Beyond the Hype: Black Market Peptides Strain Vital Health Services
The booming trade in unregulated peptides for weight loss and body enhancement is placing unprecedented pressure on essential harm reduction services, originally established to combat the HIV epidemic. This article delves into the challenges, risks, and urgent needs arising from this new wave of drug use.
7 min read
Amazon Stocks Oral Ozempic Pills: Same-Day Delivery & Pricing Guide
Amazon Pharmacy is expanding access to oral GLP-1 medications like Ozempic and Wegovy through kiosks and same-day delivery. Here is everything you need to know about pricing, logistics, and managing your treatment.
7 min read
FDA Approves Eli Lilly's Foundayo GLP-1 Pill, Stock Jumps 5%
Eli Lilly's shares surged more than 5% following FDA approval of Foundayo, its new once-daily GLP-1 weight-loss pill that can be taken anytime without food restrictions. This oral option intensifies competition with Novo Nordisk's Wegovy and Ozempic, offering real-world convenience for overweight adults. Discover the trial results, comparisons, and implications for obesity treatment.
4 min read
PPH ETF: Drug Pricing Policy & Eli Lilly Risks in 2026
The VanEck Pharmaceutical ETF (PPH) offers broad pharma exposure but faces headwinds from U.S. drug pricing reforms and heavy Eli Lilly weighting. Down 8% in the past month despite 15% one-year gains, PPH's diversification is tested. Key risks include MFN pricing deals and GLP-1 competition.
5 min read
Morning Squawk: Dow Streak, Fertilizer Prices, Novo Nordisk Wegovy & More
The latest Morning Squawk highlights the Dow's ongoing losing streak, climbing fertilizer prices, and Novo Nordisk's new Wegovy shot amid market volatility. President Trump ramps up criticism of Fed Chair Jerome Powell, urging continued investigation into the 'incompetent' leader. A judge's subpoena block adds tension to Trump's Fed nominee confirmation.
5 min read
Novo, Hims End GLP-1 Feud, Partner Again on Wegovy
The months-long GLP-1 feud between Novo Nordisk and Hims & Hers Health is over, with a new partnership to sell Wegovy via Hims' telehealth platform expected Monday. Following a recent lawsuit over copycat drugs, shares surged: Hims nearly 40%, Novo 2% after-hours. Analysts call it a surprise positive for expanded market reach.
5 min read
Novo Nordisk Investigated Over CagriSema Trial Results - NVO
Novo Nordisk faces an investor investigation by DJS Law Group over claims of misleading statements about its CagriSema weight loss drug trial. The phase 3 study failed to demonstrate non-inferiority against Eli Lilly's tirzepatide after 84 weeks, triggering a sharp 15%+ premarket stock plunge on February 23, 2026. Investors affected by the drop may have rights under securities laws.
5 min read
Viking Therapeutics Shares Surge 12% as Novo's CagriSema Stumbles
Shares of Viking Therapeutics surged approximately 12% on Monday following a clinical setback for Novo Nordisk's next-generation obesity drug CagriSema, which underperformed Eli Lilly's Tirzepatide in a pivotal Phase 3 trial. This shift highlights intensifying competition in the GLP-1 obesity market. Investors are eyeing Viking's VK2735 as a promising contender.
5 min read
Forget Ozempic: Intuitive Surgical Thrives No Matter GLP-1 Winner
Wall Street fixates on GLP-1 giants like Novo Nordisk's Ozempic and Eli Lilly, but Intuitive Surgical continues to thrive with its da Vinci surgical robots. With 11,106 systems installed by end of 2025 and procedures up 18%, this device maker is set for growth regardless of the weight loss drug race. Learn why investors should consider ISRG shares.
5 min read
Lilly Stockpiles $1.5B Orforglipron Ahead of FDA Approval Signal
Eli Lilly is sending a clear signal of confidence in its upcoming GLP-1 obesity pill, orforglipron, by stockpiling $1.5 billion worth of inventory ahead of FDA approval. This move, up from $550 million last year, anticipates robust demand without the supply chain issues that plagued injectables like Wegovy from 2022-2024. Here's what it means for patients seeking oral weight loss options.
5 min read
GLP-1 Drugs' Wide Reach: Beyond Weight Loss to Economy
GLP-1 drugs such as Ozempic and Wegovy have surged in popularity, with one in eight U.S. adults using them for weight loss or chronic conditions. Beyond shedding pounds, these medications are disrupting economies by curbing appetites and cravings. This guide dives into the clinical mechanisms and real-world impacts on food, fashion, fitness, and beyond.
4 min read
Ozempic Era Over? BMJ Study on GLP-1 Weight Regain
The Ozempic hype may fade as a BMJ study shows users regain lost weight within 1.5 years after stopping GLP-1 drugs. These medications reduce appetite but require lifelong use and lifestyle changes for lasting results. Obesity stems from systemic issues like convenience culture and ultra-processed foods, not just willpower.
3 min read
GLP-1 Drugs Reshaping Eating Habits in Connecticut
GLP-1 weight-loss drugs like Ozempic and Wegovy are changing how people in Connecticut eat, boosting demand for protein-rich foods to combat muscle loss. Nutrition experts and restaurateurs note shifts toward balanced meals and smaller portions. A clinical epidemiologist reveals how these drugs suppress appetite and delay gastric emptying for significant weight reduction.
4 min read
Reasons for the Hype Around Wegovy -- And Its Actual Significance for Investing in Novo Nordisk
Novo Nordisk has shifted its focus with Wegovy, a groundbreaking GLP-1 injection for weight management, driving significant interest and market shifts. This article explores the drug's efficacy, market forces, and potential impacts on the company's shares. Investors should consider the opportunities and risks tied to this transformative product.
6 min read
GLP-1 Pill Clearance Drives Food Companies to Protein and Scaled-Down Servings
The recent approval of GLP-1 weight-loss pills by the FDA is influencing food companies to adapt by emphasizing protein and reducing portion sizes. Analysts predict broader adoption of these pills will accelerate changes in consumer eating habits and industry offerings. Companies like Conagra and Nestle are already reformulating products to cater to this growing market.
4 min read
Jim Cramer: Eli Lilly's GLP-1 Pill Will 'Revolutionize Everything'
Jim Cramer commented on Eli Lilly's GLP-1 pill, anticipating a revolutionary impact. He also assessed other portfolio holdings, including Taiwan Semi, Chevron, SL Green, and Microsoft, providing insights into their respective sectors.
2 min read
Chinese Pharmaceutical Sector on the Verge of Global Expansion
China's pharmaceutical industry is rapidly ascending on the global stage, fueled by innovation and strategic alliances with Western companies. This rise presents both opportunities and challenges as China aims to become a major player in drug discovery and development.
7 min read